- DelMar Pharmaceuticals (DMPI) -41% on equity offering.
- Vascular Biogenics (VBLT) -13% as radiographic analysis of VB-111 Phase 2 and Phase 3 studies in recurrent GBM showed a survival benefit associated with objective responses to the compound and a distinct signature of VB-111 activity.
- Centene (CNC) -8%.
- Ability (ABIL) -8%.
- Eltek (ELTK) -7%.
- Stellar Biotechnologies (SBOT) -5%.
- Vical (VICL) -6% on merger with Brickell.